Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 70.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,571 shares of the biotechnology company’s stock after buying an additional 13,060 shares during the quarter. Intech Investment Management LLC’s holdings in Blueprint Medicines were worth $2,754,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in Blueprint Medicines by 22.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after buying an additional 729,055 shares during the last quarter. State Street Corp boosted its holdings in shares of Blueprint Medicines by 16.2% during the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after purchasing an additional 385,818 shares during the last quarter. William Blair Investment Management LLC boosted its holdings in shares of Blueprint Medicines by 16.1% during the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock worth $169,616,000 after purchasing an additional 269,896 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Blueprint Medicines by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock worth $136,942,000 after purchasing an additional 20,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Blueprint Medicines by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 604,397 shares of the biotechnology company’s stock worth $52,716,000 after purchasing an additional 7,165 shares during the last quarter.

Blueprint Medicines Trading Up 1.0 %

NASDAQ:BPMC opened at $90.48 on Thursday. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The firm has a market capitalization of $5.78 billion, a PE ratio of -83.78 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business’s 50-day moving average is $99.49 and its two-hundred day moving average is $93.96.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Wolfe Research initiated coverage on Blueprint Medicines in a report on Tuesday. They set an “outperform” rating on the stock. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Stephens restated an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $125.70.

Insider Transactions at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $102.28, for a total value of $511,400.00. Following the completion of the sale, the director now directly owns 157,557 shares of the company’s stock, valued at approximately $16,114,929.96. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,334 shares of company stock valued at $3,103,512. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.